Biomarker Predicts Anthracycline-caused Heart Damage in Women with Breast Cancer
Anthracyclines, while effective, are limited by a cumulative dose-dependent cardiotoxicity.
A genetic biomarker predicts anthracycline-induced congestive heart failure (CHF) risk among women who undergo chemotherapy for breast cancer, according to findings from a biomarker discovery study published in Clinical Cancer Research.1
Eleven single nucleotide polymorphisms (SNPs) were significantly associated with CHF, reported lead study author Bryan P. Schneider, MD, associate professor of medicine at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, and coauthors.
Of these SNPs, one called rs28714259 was strongly associated with increased CHF (odds ratio [OR] 1.9; P = .04) and decreased cardiac left-ventricular ejection fraction (OR 4.2; P = .018), they reported.
The researchers performed the genome-wide association SNPs analysis for 3431 patients who participated in the randomized phase 3 E5103 adjuvant breast cancer trial. Findings were then validated in the ECOG-1199 and BEATRICE phase 3 adjuvant therapy clinical trials.The candidate rs28714259 biomarker might provide additional information to clinicians for planning patients' personalized breast cancer treatments, the authors concluded.
1. Schneider BP, Shen F, Gardner L, et al. Genome-wide association study for anthracycline-induced congestive heart failure. Clin Cancer Res. December 19, 2016. doi: 10.1158/1078-0432.CCR.16-0908. [Epub ahead of print]